TY - GEN
T1 - Monte carlo simulation to determine conditions for optical molecular imaging of vascular disease
AU - Madzivire, Mambidzeni
AU - Riederer, Christopher
AU - Greenleaf, James
PY - 2008
Y1 - 2008
N2 - Atherosclerosis is a significant contributor to cardiovascular disease, which is a leading cause of death in the United States. Optical imaging is emerging as a promising molecular imaging tool to detect the biomarkers of vascular disease and plaque vulnerability. We describe a Monte Carlo method of investigating the use of targeted fluorescent nanoparticles as a reporter agent for optical molecular imaging. In particular, we used the model to provide insight into the optimum excitation and emission wavelengths for in vivo imaging in the presence of blood and autofluorescence.
AB - Atherosclerosis is a significant contributor to cardiovascular disease, which is a leading cause of death in the United States. Optical imaging is emerging as a promising molecular imaging tool to detect the biomarkers of vascular disease and plaque vulnerability. We describe a Monte Carlo method of investigating the use of targeted fluorescent nanoparticles as a reporter agent for optical molecular imaging. In particular, we used the model to provide insight into the optimum excitation and emission wavelengths for in vivo imaging in the presence of blood and autofluorescence.
KW - Atherosclerosis
KW - Molecular imaging
KW - Monte Carlo
KW - Optical imaging
KW - Quantum dots
UR - http://www.scopus.com/inward/record.url?scp=51049096786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51049096786&partnerID=8YFLogxK
U2 - 10.1109/ISBI.2008.4540959
DO - 10.1109/ISBI.2008.4540959
M3 - Conference contribution
AN - SCOPUS:51049096786
SN - 9781424420032
T3 - 2008 5th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, Proceedings, ISBI
SP - 169
EP - 172
BT - 2008 5th IEEE International Symposium on Biomedical Imaging
T2 - 2008 5th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, ISBI
Y2 - 14 May 2008 through 17 May 2008
ER -